Home
>
National Drug Code (NDC)
>
Lamivudine
Lamivudine - 52125-016-02 - (Lamivudine)
Drug Information of Lamivudine
| Product NDC: | 52125-016 |
| Proprietary Name: | Lamivudine |
| Non Proprietary Name: | Lamivudine |
| Active Ingredient(s): | 300 mg/1 & nbsp; Lamivudine |
| Administration Route(s): | ORAL |
| Dosage Form(s): | TABLET, FILM COATED |
| Coding System: | National Drug Codes(NDC) |
Labeler Information of Lamivudine
| Product NDC: | 52125-016 |
| Labeler Name: | REMEDYREPACK INC. |
| Product Type: | HUMAN PRESCRIPTION DRUG |
| FDA Application Number: | ANDA202032 |
| Marketing Category: | ANDA |
| Start Marketing Date: | 20130328 |
Package Information of Lamivudine
| Package NDC: | 52125-016-02 |
| Package Description: | 30 TABLET, FILM COATED in 1 BLISTER PACK (52125-016-02) |
NDC Information of Lamivudine
| NDC Code | 52125-016-02 |
| Proprietary Name | Lamivudine |
| Package Description | 30 TABLET, FILM COATED in 1 BLISTER PACK (52125-016-02) |
| Product NDC | 52125-016 |
| Product Type Name | HUMAN PRESCRIPTION DRUG |
| Non Proprietary Name | Lamivudine |
| Dosage Form Name | TABLET, FILM COATED |
| Route Name | ORAL |
| Start Marketing Date | 20130328 |
| Marketing Category Name | ANDA |
| Labeler Name | REMEDYREPACK INC. |
| Substance Name | LAMIVUDINE |
| Strength Number | 300 |
| Strength Unit | mg/1 |
| Pharmaceutical Classes | Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Nucleoside Analog [Chemical/Ingredient],Nucleoside Reverse Transcriptase Inhibitors [MoA] |
